Phase 1 Study of AMXT 1501 and DFMO for Neuroblastoma and CNS Tumors
A clinical trial is underway to evaluate the combination of AMXT 1501 and eflornithine (DFMO) for treating neuroblastoma and CNS tumors.
Company
Pharmaceutical intelligence for Aminex Therapeutics, Inc. with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.